Search Results - "Bonaca, M"

Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study by Bonaca, M P, Lesén, E, Giannitsis, E, Hedberg, J, Jernberg, T, Lambrelli, D, Duong, M, Maggioni, A P, Ariza-Solé, A, ten Berg, J, Storey, R F

“…Abstract Background Guidelines recommend extended dual antiplatelet therapy, including ticagrelor 60 mg twice daily, in high-risk post-myocardial infarction…”
Get full text

Prediction of cardiovascular risk in patients type 2 diabetes using the SCORE2-Diabetes risk score by Cavender, M, Sorensen, A, Bonaca, M, Cannon, C, Clemmensen, K, Buse, J, Kvist, K

“…Abstract Background/Introduction The SCORE2-Diabetes risk score was developed to predict the risk of cardiovascular events (CV-death, non-fatal MI and…”
Get full text

Applicability of VICTORION-1 PREVENT Criteria to the US Population by Aggarwal, R, Bhatt, D, Bonaca, M, Deck, C, Lesogor, A, Patel, M, Stroes, E, Taub, P, Windecker, S

“…Abstract Background VICTORION-1 PREVENT (V-1P) is an ongoing randomized clinical trial comparing inclisiran sodium 300mg every six months with placebo for…”
Get full text

Baseline patient reported outcomes in patients with peripheral artery disease and type 2 diabetes from STRIDE: a phase 3, 52-week, randomised, double-blind, placebo-controlled trial by Verma, S, Catarig, A, Hansen, Y, Houlind, K, Ramesh, C, Ludvik, B, Nordanstig, J, Rasouli, N, Sourij, H, Bonaca, M

“…Abstract Introduction Lower extremity peripheral artery disease (PAD) is caused by atherosclerotic steno-occlusive arterial lesions in the lower extremities…”
Get full text

Temporal shift in heart failure diagnoses among hospitalized patients within a large US integrated health system by Gluckman, T, Chiu, S T, Rider, D, Tseng, P, Mudd, J, Remick, J, Canonico, M, Bonaca, M

“…Abstract Background Heart failure (HF) is a major cause of morbidity and mortality. Its rising prevalence and attributable cost have also made it a key focus…”
Get full text

Reduction in the risk of major adverse limb events with ezetimibe versus placebo in addition to statin therapy: insights from the IMPROVE IT trial by Bonaca, M, Giugliano, R P, Cannon, C P, Park, J G, Murphy, S A, Creager, M A, Braunwald, E, Sabatine, M S

“…Abstract Background/Introduction Patients with peripheral artery disease (PAD) are at risk of developing progressive symptoms leading to revascularization as…”
Get full text

Lipoprotein(a) and the risk of major adverse limb events in patients with stable atherosclerotic vascular disease by Bonaca, M, Morrow, D A, Giugliano, R P, Scirica, B M, Palazzolo, M G, Jarolim, P, Creager, M A, O'donoghue, M, Sabatine, M S

“…Abstract Background/Introduction Patients with atherosclerotic vascular disease are at heightened risk of ischemic events, including adverse limb events. The…”
Get full text

Geographic differences in serious bleeding event rates and clinical profiles among patients with ESKD who receive peritoneal or hemodialysis, 2009-2022 by Bonaca, M P, Coyle, C, Bash, L D, Barash, I, Ramey, D R, Guedes, M, Zhao, J, Karaboyas, A, Pecoits-Filho, R, Atkins, G B

“…Abstract Background Patients with end-stage kidney disease (ESKD) have higher rates of bleeding compared to the general population. Therapies to manage risk of…”
Get full text

Acute arterial events across all vascular territories in the FOURIER trial by Oyama, K, Giugliano, R, Tang, M, Bonaca, M, Saver, J, Murphy, S, Ruzza, A, Sever, P, Sabatine, M, Bergmark, B

“…Abstract Background In the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) trial, adding the PCSK9…”
Get full text

Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease: rationale and design of the STRIDE trial by Sillesen, H, Debus, E S, Enggaard, R B B, Frenkel, O, Heled, Y, Mansor-Lefebvre, S, Bonaca, M P

“…Abstract Background/Introduction Lower extremity peripheral arterial disease (PAD) is a severe form of atherosclerotic cardiovascular (CV) disease. The…”
Get full text

Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trial by Patel, S, Morrow, D, Bonaca, M, Palazzolo, M, Jarolim, P, Steg, P G, Bhatt, D, Storey, R, Cohen, M, Braunwald, E, Sabatine, M, O'Donoghue, M

“…Abstract Background Lp(a) plays a causal role in atherogenesis and may exert pro-thrombotic effects by inhibiting fibrinolysis owing to its structural homology…”
Get full text

Evaluation of the benefit of rivaroxaban on VOYAGER PAD primary composite of limb, heart and brain outcomes using the global rank and win ratio methods by Bonaca, M, Debus, S, Nehler, M, Anand, S, Patel, M, Pap, A F, Deng, H, Hodge, S, Szarek, M, Haskell, L, Muehlhofer, E, Berkowitz, S, Bauersachs, R

“…Abstract Background/Introduction The VOYAGER PAD trial demonstrated that rivaroxaban 2.5 mg twice daily added to background antiplatelet therapy reduced a…”
Get full text

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial by O’Donoghue, Michelle L, Glaser, Ruchira, Cavender, Matthew A, Aylward, Philip E, Bonaca, Marc P, Budaj, Andrzej, Davies, Richard Y, Dellborg, Mikael, Fox, Keith A. A, Gutierrez, Jorge Antonio T, Hamm, Christian, Kiss, Robert G, Kovar, František, Kuder, Julia F, Im, Kyung Ah, Lepore, John J, Lopez-Sendon, Jose L, Ophuis, Ton Oude, Parkhomenko, Alexandr, Shannon, Jennifer B, Spinar, Jindrich, Tanguay, Jean-Francois, Ruda, Mikhail, Steg, P. Gabriel, Theroux, Pierre, Wiviott, Stephen D, Laws, Ian, Sabatine, Marc S, Morrow, David A

“…IMPORTANCE: p38 Mitogen-activated protein kinase (MAPK)–stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive…”
Get full text

Exome sequencing in over 63,000 patients in TIMI trials uncovers pathogenic cardiomyopathy variant carriers with high risk for heart failure and cardiovascular death by Kany, S, Melloni, G E M, Jurgens, S J, Berg, D, Bonaca, M, Giugliano, R P, Wiviott, S D, Bhatt, D L, Steg, P G, Raz, I, Pirruccello, J P, Sabatine, M S, Ruff, C T, Ellinor, P T, Marston, N A

“…Abstract Background Rare genetic variants predisposing to cardiomyopathy (CMP) confer increased risk for adverse events. The prevalence of CMP variants in…”
Get full text

Pathogenic cardiomyopathy gene variants inform prognosis in atrial fibrillation: results from exome sequencing in over 17,000 patients in TIMI trials by Jurgens, S, Melloni, G E M, Kany, S, Berg, D D, Bonaca, M P, Giugliano, R P, Wiviott, S D, Bhatt, D L, Steg, P G, Raz, I, Pirruccello, J P, Sabatine, M S, Marston, N A, Ellinor, P T, Ruff, C T

“…Abstract Background Rare genetic variants in cardiomyopathy genes are associated with risk of atrial fibrillation (AF), even in the absence of overt…”
Get full text

CO8 Design and Rationale of a Global Prospective Observational Study of Real-World Management of Patients with Atrial Fibrillation at High Risk of Stroke- Gardenia by Kakkar, A., Bonaca, M., Giugliano, R.P., Bloomfield, D., Pieper, K., Yi, B.A., Salter, J., Freedholm, D., Parkar, S., Glasspool, J., Kayani, G., Fox, K.A.A.

Get full text

Total hospitalizations after peripheral arterial revascularization in the VOYAGER trial by Szarek, M, Debus, E S, Nehler, M R, Anand, S S, Patel, M R, Haskell, L P, Muehlhofer, E S, Berkowitz, S D, Bauersachs, R M, Bonaca, M P

“…Abstract Background In the VOYAGER PAD trial, rivaroxaban reduced first and total (first and subsequent) occurrences of major adverse limb and cardiovascular…”
Get full text

Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial by Magnani, Giulia, Storey, Robert F, Steg, Gabriel, Bhatt, Deepak L, Cohen, Marc, Kuder, Julia, Im, Kyungah, Aylward, Philip, Ardissino, Diego, Isaza, Daniel, Parkhomenko, Alexander, Goudev, Assen R, Dellborg, Mikael, Kontny, Frederic, Corbalan, Ramon, Medina, Felix, Jensen, Eva C, Held, Peter, Braunwald, Eugene, Sabatine, Marc S, Bonaca, Marc P

“…We evaluated the relationship of renal function and ischaemic and bleeding risk as well as the efficacy and safety of ticagrelor in stable patients with prior…”
Get full text

PB1097 Cost of Major Thrombotic Cardiovascular Events (MTCVE) Among US Patients with and without End-Stage Kidney Disease (ESKD) by Bash, L., Roetker, N., Victores, A., Ramey, D., Wetmore, J., Bonaca, M.

Get full text

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial by Cavender, Matthew A, Scirica, Benjamin M, Bonaca, Marc P, Angiolillo, Dominick J, Dalby, Anthony J, Dellborg, Mikael, Morais, Joao, Murphy, Sabina A, Ophuis, Ton Oude, Tendera, Michal, Braunwald, Eugene, Morrow, David A

“…BACKGROUND—Vorapaxar reduces cardiovascular death, myocardial infarction (MI), or stroke in patients with previous MI while increasing bleeding. Patients with…”
Get full text